Establishing causality from case reports: Was ephedra to blame?

Southern Medical Journal

Volumn 99, Issue 5, 2006, Pages 453-454

  Bent, Stephen ^a,b  

^a Osher Center for Integrative Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHEDRA EXTRACT;

AUTONOMIC DYSFUNCTION; DIET SUPPLEMENTATION; EDITORIAL; EPHEDRA; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEART PALPITATION; HUMAN; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RISK FACTOR; STROKE; VOMITING;

EPHEDRA; HUMANS; MEDICAL RECORDS; NEUROTOXICITY SYNDROMES; PLANT PREPARATIONS;

EID: 33744469842     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000216420.60005.a4     Document Type: Editorial

References (11)

1. U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition. Dietary Supplements: Ephedrine Alkaloids. Available at http://www.cfsan.fda.gov/dms/ds-ephed.html. Accessed December 22, 2005.
2. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-1838.
3. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002;77:12-16.
4. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. J Clin Psychopharmacol 1997;17:437-439.
5. Zahn KA, Li RL, Purssell RA. Cardiovascular toxicity after ingestion of 'herbal ecstacy'. J Emerg Med 1999;17:289-291.
6. Moawad FJ, Hartzell JD, Biega TJ, et al. Transient blindness due to posterior reversible encephalopathy syndrome following ephedra overdose. South Med J 2006;99:511-514.
7. Jones JK. Determining causation from case reports. In: Strom BL, ed. Pharmacoepidemiology. West Sussex, England, John Wiley & Sons Ltd, 2000, pp 525-552.
8. Haller CA, Jacob P, Benowitz NL. Short-term metabolic and hemodynamic effects of ephedra and guarana combinations. Clin Pharmacol Ther 2005;77:560-571.
9. Hardman JG, Limbird LE, eds. In: Goodman & Gilman's the Pharmacological Basis of Therapeutics. 10th ed. New York, McGraw-Hill, 2001.
10. Morgenstern LB, Viscoli CM, Kernan WN, et al. Use of ephedra-containing products and risk for hemorrhagic stroke. Neurology 2003;60:132-135.
11. Shekelle P, Morton S, Maglione M, et al. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects. Evidence Report/Technology Assessment No. 76 (Prepared by Southern California Evidence-based Practice Center, RAND, under Contract No. 290-97-0001, Task Order No. 9). AHRQ Publication No. 03-E022. Rockville, MD, Agency for Healthcare Research and Quality, 2003.